Moody's came out with an analysis today saying the requirement could be slightly good for for-profit hospitals (Bad-debt charges will decline. The expansion of healthcare coverage under the law will lessen for-profit hospital operatorsâ€™ exposure to bad debts, which in turn will improve margins and cash flow. However, we expect that the growth rate of Medicare reimbursements will also slow down, offsetting the benefit of lower bad-debt expense and making the overall credit impact of the ruling neutral to slightly positive), negative for pharmaceutical cos. (Pharmaceutical companies will continue to pay for the full adoption of the Affordable Care Act in the form of higher rebates to the government for Medicaid drug costs, discounts to seniors covered under Medicare Part D drug plans and a new industry fee) and slightly negative for medical device firms (Beginning Jan. 1, 2013, US medical-device product sales will be subject to a 2.3% excise tax; the excise tax will be tax-deductible, resulting in an estimated effective tax rate of 1.5% on US device revenues).